Abstract: An object of the present invention is to elucidate a molecular mechanism of ligand-independent activation of EphA2 in cancer cells, make EphA2 a more useful target in the treatment of cancer, and provide a cancer testing method and the like using the mechanism. The present invention provides, for example, a cancer testing method including a step of measuring an amount of an EphA2 protein fragment having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject.
Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
August 2, 2022
Assignee:
AGENSYS, INC.
Inventors:
Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
Type:
Grant
Filed:
April 11, 2017
Date of Patent:
July 19, 2022
Assignee:
Symphogen A/S
Inventors:
Trine Lindsted, Torben Gjetting, Gunther Roland Galler, Monika Gad, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
Type:
Grant
Filed:
June 14, 2021
Date of Patent:
July 19, 2022
Assignee:
TeneoTwo, Inc.
Inventors:
Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Udaya Rangaswamy
Abstract: The use of model T cell receptors (TCRs) as scaffolds for in vitro engineering of novel specificities is provided. TCRs with de novo binding to a specific peptide-major histocompatibility complex (MHC) product can be isolated by: 1) mutagenizing a T cell receptor protein coding sequence to generate a variegated population of mutants (a library), 2) selection of the library of TCR mutants with the specific peptide-MHC, using a process of directed evolution and a “display” methodology (e.g., yeast, phage, mammalian cell) and the peptide-MHC ligand. The process can be repeated to identify TCR variants with improved affinity for the selecting peptide-MHC ligand.
Abstract: The present invention relates to the identification of biological markers of ovarian cancer. Specifically, cancer-associated autoantibodies to ANXA1, ARP3, SAHH, SERPH, ARAP1, OTUB1, ATP1A1, UBA1, and CFAH have been identified in subjects with early stage ovarian cancer. These autoantibodies can be utilised for a range of purposes including methods for detecting ovarian cancer, methods for screening for early stage ovarian cancer, and methods for assessing treatment response as well as disease progression and recurrence. The autoantibodies also represent prognostic markers of ovarian cancer development.
Type:
Grant
Filed:
January 11, 2019
Date of Patent:
June 28, 2022
Assignee:
ADELAIDE RESEARCH & INNOVATION PTY LTD
Inventors:
Peter Hoffmann, Martin Oehler, Karina Martin
Abstract: This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer. The invention also includes a method of treating viral infections using a sdAb, wherein the sbAb inhibits the replication of viruses such as Ebola virus and Zika virus in infected cells.
Abstract: A method of identifying cancer patients who would be responsive to bladder sparing surgery plus chemoradiation therapy or cystectomy using expression of MRE11 in a nuclear to cytoplasmic ratio is presented.
Type:
Grant
Filed:
August 7, 2019
Date of Patent:
June 14, 2022
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor.
Type:
Grant
Filed:
March 27, 2019
Date of Patent:
May 10, 2022
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
April 19, 2022
Assignee:
The United States of America, as represented by the Secretary Department of Health and Human Services
Inventors:
Rami Yoseph, Paul F. Robbins, Steven A. Rosenberg
Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.
Type:
Grant
Filed:
October 31, 2016
Date of Patent:
March 8, 2022
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine
Inventors:
Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner
Abstract: The present invention relates generally to a method of prognosing the survival of a patient with a breast neoplasm, more particularly a patient with a breast neoplasm which is estrogen receptor-/progesterone receptor-/HER-2-(“triple-negative”). The method of the present invention more particularly provides a method for prognosing breast cancer patient survival, in particular risk of metastatic spread, by screening for IRF9 expression. In a related aspect, the present invention provides a method of therapeutically or prophylactically treating patients with a triple-negative breast neoplasm, in particular those patients with triple-negative breast neoplasia which is characterised by a poor survival prognosis, still more particularly a high risk of metastatic spread, by upregulating type I IFN levels.
Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
January 18, 2022
Assignee:
Compugen Ltd.
Inventors:
Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.
Type:
Grant
Filed:
April 23, 2018
Date of Patent:
January 4, 2022
Assignee:
President and Fellows of Harvard College
Inventors:
David R. Liu, Alexis Christine Komor, Holly A. Rees, Yongjoo Kim
Abstract: The present invention relates to specific antibodies and use thereof, such as for identifying and/or quantifying liraglutide fibrils and/or semaglutide fibrils.
Type:
Grant
Filed:
March 31, 2020
Date of Patent:
December 28, 2021
Assignee:
Novo Nordisk A/S
Inventors:
Peter Matthew Tessier, Samuel D. Stimple, Arne Staby
Abstract: A binding molecule specific for CD73 and a use of the binding molecule. Specifically, provided are a separate antibody binding CD73 and inhibiting the activity of CD73 or an antigen binding part of the separate antibody, and a use of the separate antibody or the antigen binding part thereof in treatment of diseases; also provided are a nucleic acid molecule encoding the separate antibody or the antigen binding part thereof, an expression vector for expressing the separate antibody or the antigen binding part thereof, a host cell, and a preparation method.
Type:
Grant
Filed:
April 26, 2021
Date of Patent:
November 16, 2021
Assignee:
JACOBIO PHARMACEUTICALS CO., LTD.
Inventors:
Qinghao Liu, Wenlai Zhou, Haiyan Yang, Hongling Wang
Abstract: Compositions, methods, systems, apparatus and/or articles of manufacture are disclosed for reducing the susceptibility of a population and/or members thereof to cancer, which may include anti-cancer vaccines, components thereof which may include novopeptides, and methods relating thereto.
Abstract: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin:total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.
Type:
Grant
Filed:
July 24, 2018
Date of Patent:
November 9, 2021
Assignees:
ALBERT EINSTEIN COLLEGE OF MEDICINE, KING'S COLLEGE LONDON
Inventors:
John Condeelis, Tony Tsz-Cheong Ng, Gregory Weitsman